Matuzumab

Manufactured by Merck Group

Sourced in Germany

Matuzumab is a laboratory equipment product offered by Merck Group. It is used for various scientific applications, but a detailed description of its core function cannot be provided in an unbiased and factual manner without the risk of extrapolation or interpretation.

Automatically generated - may contain errors

Lab products found in correlation

Pd 10 column, by GE Healthcare (1 mentions) Cetuximab, by Merck Group (1 mentions)

Spelling variants of this product

Cetuximab and matuzumab antibodies (2 citations)

2 protocols using matuzumab

Radiolabeling of Anti-EGFR Monoclonal Antibody

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The anti-EGFR-MAb (matuzumab; Merck, Darmstadt, Germany) was conjugated with the ²¹³Bi chelating agent SCN-CHX-A”-diethylenetriaminepentaacetic acid (DTPA) (Macrocyclics, Plano, TX, USA) prior to radiolabelling as previously described^{16 (link)}. The α-emitter ²¹³Bi was eluted from an ²²⁵Ac/²¹³Bi generator system provided by the Directorate for Nuclear Safety and Security (JRC, EC, Karlsruhe, Germany)^{12 (link),17 (link)}. CHX-A”-DTPA–chelated anti-EGFR-MAb (100 µg) was incubated with the ²¹³Bi eluate (37–148 MBq) in 0.4 M ammonium acetate buffer at pH 5.3 for 7 min at room temperature. Unbound ²¹³Bi was separated via size-exclusion chromatography using PD-10 columns (GE Healthcare, Munich, Germany). Purity of ²¹³Bi-anti-EGFR conjugates was controlled as described earlier^{18 (link)}. Survival was assessed by microscopical analysis as described previously (see also^{15 (link)}).

Feuerecker B., Biechl P., Seidl C., Bruchertseifer F., Morgenstern A., Schwaiger M, & Eisenreich W. (2021). Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate. Scientific Reports, 11, 6227.

+ Open protocol

+ Expand

Binding Assay of Anti-EGFR Fabs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Phage mini preps of Fab clones belonging to the different superclusters were tested for binding to CHO cell clones stably expressing either wtEGFR or EGFR-variant III in FACS, as described above.
Anti-EGFR Fabs (as Fabs expressed on phage) were tested for binding to EGFR in the presence of an excess of control, literature-derived IgG, namely ICR10 (Abcam cat# ab231; domain I), EGFR.1 (Thermo Scientific cat# MS-311-P; domain II), Matuzumab (made in house; domain III), or cetuximab (Merck clinical batch; domain III) as described in Cochran et al. 64

Herpers B., Eppink B., James M.I., Cortina C., Cañellas-Socias A., Boj S.F., Hernando-Momblona X., Glodzik D., Roovers R.C., van de Wetering M., Bartelink-Clements C., Zondag-van der Zande V., Mateos J.G., Yan K., Salinaro L., Basmeleh A., Fatrai S., Maussang D., Lammerts van Bueren J.J., Chicote I., Serna G., Cabellos L., Ramírez L., Nuciforo P., Salazar R., Santos C., Villanueva A., Stephan-Otto Attolini C., Sancho E., Palmer H.G., Tabernero J., Stratton M.R., de Kruif J., Logtenberg T., Clevers H., Price L.S., Vries R.G.J., Batlle E, & Throsby M. (2022). Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nature cancer, 3(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!